Northwest's DCVax-Direct doesn't meet tumor response criteria, TheStreet says None of 19 patients with advanced, metastatic cancers in an ongoing phase I trial have responded to treatment with Northwest Biotherapeutics' DCVax-Direct as defined by a standard known as RECIST, or Response Evaluation Criteria in Solid Tumors, which says partial response requires a 30% reduction in the size of the target lesion, according to TheStreet's Adam Feuerstein. Northwest's CEO Linda Powers said the greatest response seen so far after DCVax-Direct injections directly into a single tumor was a 28% reduction, according to Feuerstein. Reference Link
News For NWBO From The Last 14 Days
Check below for free stories on NWBO the last two weeks.